NVCT
Nuvectis Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$18.44
−0.71%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -28.7%
- EBIT
- -25.7%
- EPS
- -13.9%
- Free cash flow
- -57.2%
- Operating cash flow
- -57.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -9.4%
Three-year CAGR
- Revenue
- —
- EBITDA
- -39.2%
- EBIT
- -38.9%
- Net income
- -39.2%
- EPS
- -18.9%
- Free cash flow
- -30.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026